KISS: Allergic Eye Disease

BMJ 2017;359:j4706

Assessment:

• History and examination:
  ○ Itching is the predominant symptom; also ask about discharge, duration of symptoms and exacerbating factors; is it seasonal? how much is it affecting quality of life?
  ○ Check visual acuity (VA); look for corneal and limbal (around the iris) irregularities; consider fluorescein stain if pain, loss of vision or photophobia

• Red flags (require acute referral):
  ○ Pain +/- photophobia; blurring or loss of vision; red eye in contact lens wearer; corneal involvement (ulcer, opacity or spots, limbal changes); recent eye surgery

• Differential diagnoses:
  ○ Infective conjunctivitis - eyes tend to be affected sequentially and discharge tends to be more mucous; URTI symptoms usually present
  ○ Other differentials include serious causes of red eye (see separate chapter/KISS on ‘corneal ulcers and acute red eye’) and dry eye disease (see chapter on ‘dry eyes’)

Causes:

• Seasonal allergic conjunctivitis (SAC) - bilateral conjunctival redness with watery/mildly mucous discharge; associated with childhood atopy; most frequent in spring and summer, triggered by pollens; often associated with nasal symptoms (rhinoconjunctivitis)

• Perennial allergic conjunctivitis (PAC) - presents as for SAC, but doesn’t follow seasonal pattern; triggered by environmental allergens e.g. house dust mites, animals, fungal spores

• Rare causes include vernal and allergic keratoconjunctivitis - severe forms of allergic eye disease; present with severe symptoms and often red flags e.g. keratitis, corneal erosions; need to be under secondary care - usually need topical steroids +/- immune suppressants

Management:

• Preventative measures:
  ○ Cold compress; avoid rubbing eyes; refrigerated preservative free lubricants (need to use >4-6 times/day); allergen avoidance (evidence for effectiveness poor)

• Acute symptoms (alone or in combination):
  ○ Topical antihistamines (AH) (e.g. azelastine) - well tolerated; only need BD application; switch to alternative if treatment failures or side effects
  ○ 2nd generation oral AH (e.g. cetirizine, loratidine)
  ○ Topical vasoconstrictors - short acting so require frequent use; can result in rebound symptoms; don’t use long term or in those with CVD or hypertension

• Chronic symptoms:
  ○ Mast cell stabilisers (e.g. sodium cromoglycate, nedocromil sodium) - need QDS application; can cause burning sensation; take several weeks to become effective
  ○ Combinations of topical AH, oral AH and mast stabilisers if single agents ineffective

• Patient information: Click here for a good patient information leaflet
  ○ Manage expectations - aim of treatment is to improve symptoms to resume normal activities not to eliminate symptoms; treatments take several weeks to suppress symptoms; outcomes are generally dependent on adherence to treatment
  ○ If patients have predictable flares, start treatment continuously for several weeks before as well as during flare periods; if flares are unpredictable or symptoms occur throughout the year, consider long term treatment

www.nbmedical.com